行情

CYCC

CYCC

Cyclacel Pharms
NASDAQ

实时行情|Nasdaq Last Sale

0.8000
+0.0710
+9.74%
盘后: 0.8000 0 0.00% 16:46 01/17 EST
开盘
0.7180
昨收
0.7290
最高
0.8005
最低
0.7000
成交量
51.40万
成交额
--
52周最高
1.180
52周最低
0.2813
市值
1,376.00万
市盈率(TTM)
-1.5218
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CYCC 新闻

  • 英国诺丁汉市开始试验无线充电的出租车
  • TechWeb.3小时前
  • 英财政大臣:脱欧后 英国“不会与欧盟结盟”
  • 中国新闻网.3小时前
  • FBI探员力挺苹果:已经为调查提供足够帮助
  • 新浪科技.3小时前
  • 亚马逊手掌支付进行终端测试 Visa等成合作伙伴
  • 新浪科技.4小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CYCC 简况

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开

Webull提供Cyclacel Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。